ImmVirX reports on operations for FY24
Melbourne, Australia 1 October 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to provide a summary of its operations for the financial year ended 30 June 2024. The principal activity during the financial year was the […]
ImmVirX presents update on Phase 1a/b Clinical Study at Medical Oncology Group of Australia Annual Meeting
Strong recruitment with 14 patients to date – four sites open + more shortly. Well tolerated, no dose-limiting toxicities. Signs of anti-cancer monotherapy activity in 2 of first 10 late-stage colorectal cancer patients evaluable for response. Late-stage colorectal cancer patient with complete response in injected lesion and no new metastatic disease over one year since […]
ImmVirX appoints Dr. Oksana Zdanska as Medical Director
Melbourne, Australia, 16 April 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generationof receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today. Dr. Zdanska is a highly regarded clinical leader with extensive experience […]
ImmVirX and Innovent Enter into Clinical Trial Collaboration to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers
ImmVirX’s Oncolytic Virus IVX037 to be assessed in combination with Innovent’s checkpoint inhibitor TYVYT® in Colorectal, Ovarian and Gastric Cancer to Investigate the Combination of IVX037 and Sintilimab in Difficult-to-treat Cancers Melbourne, Australia 21st February 2024 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients […]
ImmVirX receives $3.77M R&D tax refund for FY23
Melbourne, Australia 12 February 2024 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, has received a $3,771,296 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D […]
CEO Malcolm McColl speaks at Bell Potter Healthcare Conference
ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl’s presentation at the Bell Potter Healthcare Conference 2023 held in November is available to view here.
ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Strong recruitment – commenced April 2023, 8 patients to date. Strong clinician interest across multiple sites. Intralesional administration well tolerated, no dose-limiting toxicities. Early signs of induction of potentially beneficial inflammatory cytokines/chemokines, such as CXCL10. Phase 1b combination with checkpoint inhibitor to open in early 2024. Melbourne, Australia 6 November 2023 – ImmVirX Pty Limited, a life […]
ImmVirX reports on operations for FY23
Melbourne, Australia 21 September 2023 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next wave of receptor-targeted oncolytic viral immunotherapies for patients confronted with common yet formidable cancers, presents a summary of its operations for the financial year ending 30 June 2023. The year was headlined by the progress of IVX037, ImmVirX’s […]
ImmVirX raising $25m led by renowned healthcare VC OneVentures
– Up to A$25 million to be raised in Series B Financing, funding ImmVirX through to 2026 – Leading healthcare venture capital investor OneVentures subscribing for A$15 million – Up to $10 million to be raised from existing shareholders and placement of any shortfall – Dr Jeannie Joughin, a Principal at OneVentures, to join ImmVirX […]
ImmVirX enters the clinic with next generation oncolytic virus
First patient on trial in colorectal, gastric and ovarian cancer study (CP-IVX001) Melbourne, Australia 11 April 2023 – ImmVirX Pty Limited, a clinical stage oncology company focused on developing next-generation, receptor targeted oncolytic viral immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, today announced that the first patient […]
